Head-to-head · free
Genmab vs Hims & Hers Health
GMAB vs HIMS — return on capital, cash generation, margins and balance sheet side by side.
GMAB
3 / 4
measures where GMAB leads
HIMS
1 / 4
measures where HIMS leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | GMAB | HIMS · FY2025 |
|---|---|---|
| Revenue | — | $2.3B |
| Net income | — | $128.4M |
| Revenue growth (yearly, multi-year) | — | 71.4% |
| Free cash flow | — | — |
| Free cash flow margin | — | — |
| Net cash / (debt) | — | — |
| ROIC | 10.1% | — |
| Return on equity | 17.5% | 25.2% |
| Gross margin | 93.6% | 73.8% |
| Operating margin | 33.6% | 4.5% |
| Net debt / EBITDA | 3.13x | 4.65x |
Figures are as reported by each company; latest fiscal year shown.
Where Hims & Hers Health's cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free